PEMBROLIZUMAB for Transitional cell carcinoma metastatic: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

There are 245 adverse event reports in the FDA FAERS database where PEMBROLIZUMAB was used for Transitional cell carcinoma metastatic.

Most Reported Side Effects for PEMBROLIZUMAB

Side Effect	Reports	%	Deaths	Hosp.
Malignant neoplasm progression	10,111	12.1%	5,124	3,426
Death	4,744	5.7%	4,737	893
Diarrhoea	4,251	5.1%	556	2,141
Fatigue	3,833	4.6%	365	1,246
Off label use	3,416	4.1%	747	1,045
Product use in unapproved indication	3,191	3.8%	514	909
Pyrexia	3,155	3.8%	444	2,194
Rash	2,900	3.5%	289	1,047
Nausea	2,670	3.2%	335	1,237
Decreased appetite	2,486	3.0%	371	1,235
Hypothyroidism	2,326	2.8%	242	935
Product use issue	2,323	2.8%	417	610
Hypertension	2,245	2.7%	276	1,118
Asthenia	2,131	2.5%	300	1,058
Interstitial lung disease	2,113	2.5%	869	1,276